Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program.

Massimo, Andreoni; Teti, Elisabetta; Antinori, Andrea; Milazzoi, Laura; Sollima, Savatore; Rizzardini, Giuliano; Di Biagio, Antonio; Saracino, Annalisa et al. · Clin Infect Dis · 2017

case_series · Level IV

Where this comes from

Record sourced from PubMed, PMID 28011605.
Also identified by DOI 10.1093/cid/ciw846.
No licence information is recorded for this record.
Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.

Abstract

Patients co-infected with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) are at high risk of liver disease progression. We report a favorable safety profile and SVR12 rates of 96.7% among HIV/HCV co-infected patients participating in an Italian compassionate-use program of ombitasvir/paritaprevir/ritonavir + dasabuvir (OBV/PTV/r + DSV) ± ribavirin (RBV).

Read the full text

View on PubMed · Publisher (DOI)